Comparative Pharmacology
Head-to-head clinical analysis: STATROL versus TRIATEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STATROL versus TRIATEX.
STATROL vs TRIATEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Statrol is a combination antibiotic ointment containing polymyxin B sulfate, neomycin sulfate, and gramicidin. Polymyxin B binds to lipopolysaccharides in the outer membrane of gram-negative bacteria, disrupting membrane integrity. Neomycin inhibits protein synthesis by binding to the 30S ribosomal subunit. Gramicidin alters cell membrane permeability in gram-positive bacteria by forming ion channels.
TRIATEX (methotrexate) inhibits dihydrofolate reductase, blocking tetrahydrofolate synthesis and thereby interfering with DNA synthesis, repair, and cellular replication. It also has immunomodulatory and anti-inflammatory effects through adenosine-mediated pathways.
10 mg orally once daily
Triatex (trianterene/hydrochlorothiazide) 37.5 mg/25 mg or 75 mg/50 mg orally once daily; may increase to maximum of 2 capsules daily.
None Documented
None Documented
Terminal half-life 12-16 hours in adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 8-12 hours (mean 10 hours) in adults with normal renal function; prolonged to 20-40 hours in moderate-severe renal impairment (CrCl <30 mL/min).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites, 10% unchanged.
Primarily renal excretion (80-90% as unchanged drug via glomerular filtration and active tubular secretion) with 5-10% fecal elimination.
Category C
Category C
Otic Antibiotic/Corticosteroid
Corticosteroid